LP412105-1
Delamanid
Active
Description
Delamanid is the first in a new class of anti-mycobacterial agents called bicyclic nitroimidazoles. It is indicated for pulmonary multidrug-resistant tuberculosis (MDR-TB) and is effective against Mycobacterium tuberculosis during replication, dormancy, and intracellular stages. It is primarily metabolized by serum albumin, and does not affect cytochrome P450 metabolic activity. In clinical trials, delamanid was associated with prolonged QTc on EKG that peaks at 8 weeks following the start of therapy and resolves within 4 weeks after stopping therapy, but which did not result in any cardiac events. PMID: 30029909 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Delamanid
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2019-11-02
- Construct for LOINC Short Name
- Delamanid
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP412105-1 - ConceptMap translate
- https:
//fhir.loinc.org/ConceptMap/$translate?system=http: //loinc.org&code=LP412105-1
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| zh-CN | Chinese (China) | 迪拉马尼 Synonyms: CAS 681492-22-8; |
| it-IT | Italian (Italy) | Delamanid |
| es-ES | Spanish (Spain) | Delamanid |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright